News

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 09, 2022

REDWOOD CITY, Calif. , Nov. 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...

Read More

Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

October 03, 2022

REDWOOD CITY, Calif. , Oct. 03, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: ...

Read More

Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

September 06, 2022

REDWOOD CITY, Calif. , Sept. 06, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...

Read More